{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075244","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.601997+00:00","generated_at":"2026-05-17T17:45:36.685794+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quoin Pharma Q2 net loss $3.7M; QRX003 advances with FDA/EMA designations","bullets":["Net loss Q2 2025 $3.7M vs $2.0M YoY; cash $7.8M supports operations into Q1 2026.","Positive 6-month pediatric Netherton data: skin improvement, reduced itch, no adverse events.","FDA cleared second pivotal study (CL-QRX003-002); NDA filing targeted later 2026.","EMA granted Orphan Drug Designation; FDA granted Rare Pediatric Disease Designation for QRX003.","Positive 12-week Peeling Skin Syndrome data: improved disease severity and quality of life."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075244","json":"https://secwatch.observer/filing/0001104659-25-075244.json","markdown":"https://secwatch.observer/filing/0001104659-25-075244.md","text":"https://secwatch.observer/filing/0001104659-25-075244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925075244/0001104659-25-075244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925075244/tm2522891d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:45:36.685794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}